Background {#S1}
==========

The 2019 novel coronavirus strain (SARS-CoV-2) originating in Wuhan, China has become a worldwide pandemic with significant morbidity and mortality estimates up to 2% of confirmed cases. The current case definition for confirmed COVID-19 due to SARSCoV-2 infection relies on PCR-positive nasopharyngeal or respiratory specimens, with testing largely determined by presence of fever or respiratory symptoms in an individual at high epidemiologic risk. However, this case definition likely underestimates the prevalence of SARS-CoV-2 infection, as individuals who develop subclinical infection that does not produce fever or respiratory symptoms are unlikely to be tested, and testing by PCR of nasopharyngeal or respiratory specimens is unlikely to be 100% sensitive in detecting subclinical infection. Widespread testing within the United States is also severely limited by the lack of available testing kits and testing capacity limitations of available public and private laboratories. Therefore, the true prevalence of SARS-CoV-2 infection is currently unknown, and the sensitivity of PCR to detect infection is also unknown.

Serology can play an important role in defining both the prevalence of and sensitivity of PCR for SARS-CoV-2 infection, particularly for subclinical infection. This point is demonstrated by analogy with influenza virus, for which a meta-analysis of available literature measured the fraction of asymptomatic infections detected by PCR as approximately 16%, while the fraction of asymptomatic infections detected by seroconversion was measured as approximately 75%^[@R1]^. The seroprevalence of common human coronaviruses is known to increase throughout childhood to near 100% by adolescence^[@R2]^. Thus, any serologic methodology to estimate prevalence of SARS-CoV-2 needs to identify and rule out cross-reactivity with these common human coronavirus strains.

One challenge in applying serology to SARS-CoV-2 is that the choice of antigen and choice of assay is less well defined for coronavirus than more well studied viruses such as influenza. However, prior approaches to serologic detection of infection with emerging coronaviruses including SARS and MERS have focused on the S1 domain of the spike (S) glycoprotein and the nucleocapsid (N) protein, which are considered the immunodominant antigens for these viruses^[@R3]^. In particular, the S1 domain is strain-specific, while the N protein shows cross-reactivity across strains.

The assay methodologies used for serologic detection of coronavirus infection include binding and neutralization assays. These methodologies have been shown to be well correlated^[@R4]^. However, neutralization assays require viral culture, which must be performed in high-level biosafety containment units for emerging coronaviruses with high epidemic potential such as SARS-CoV-2. Conversely, binding assays such as ELISA can be readily performed with widely available reagents and equipment so are field deployable and suitable for point of care testing.

The protein microarray methodology has been widely used to simultaneously perform binding assays against hundreds of antigens printed onto a nitrocellulose-coated slide for detection of multiple antibody isotypes^[@R5]^. This methodology was recently demonstrated for simultaneous measurement of IgG and IgA antibodies against over 250 antigens from diverse strains and subtypes of influenza^[@R6]^. This methodology has previously been applied to detect antibodies against the S1 domains of SARS and MERS coronaviruses^[@R7]^.

Methodology {#S2}
===========

Specimen Collection {#S3}
-------------------

The blood specimens used in this study were collected for a larger study where residents of a college resident community in an Eastern university were monitored prospectively to identify acute respiratory infection (ARI) cases using questionnaires and RT-qPCR, so as to characterize contagious phenotypes including social connections, built environment, and immunologic phenotypes^[@R8]^. From among de-identified blood specimens for which future research use authorization was obtained, five specimens that showed high IgG reactivity against human coronaviruses in the larger study were chosen for validation of the coronavirus antigen microarray.

Antigen Microarray {#S4}
------------------

The coronavirus antigen microarray used in this investigation includes 67 antigens across subtypes expressed in either baculovirus or HEK-293 cells (see [Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}). These antigens were provided by Sino Biological Inc. (Wayne, PA) as either catalog products, or service products. The antigens were printed onto microarrays, probed with human sera, and analyzed as previously described ([Figure 1](#F1){ref-type="fig"})^[@R6],[@R9],[@R10]^.

Briefly, lyophilized antigens were reconstituted to a concentration of 0.1 mg/mL in phosphate-buffered saline (PBS) with 0.001% Tween-20 (T-PBS) and then printed onto nitrocellulose-coated slides from Grace Bio Labs (GBL, Bend, OR) using an OmniGrid 100 microarray printer (GeneMachines). The microarray slides were probed with human sera diluted 1:100 in 1x GVS Fast Blocking Buffer (Fischer Scientific) overnight at 4°C, washed with T-TBS buffer (20 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-20 in ddH~2~O adjusted to pH 7.5 and filtered) 3 times for 5 minutes each, labeled with secondary antibodies to human IgG conjugated to quantum dot fluorophore for 2 hours at room temperature, and then washed with T-TBS 3 times for 5 minutes each and dried. The slides were imaged using ArrayCam imager (Grace Bio Labs, Bend, OR) to measure background-subtracted median spot fluorescence. Non-specific binding of secondary antibodies was subtracted using saline control. Mean fluorescence of the 4 replicate spots for each antigen was used for analysis.

Statistical Analyses {#S5}
--------------------

Descriptive statistics were used to summarize the IgG reactivity as measured by mean fluorescence across antigen replicates. T-test or F-test were used to test for the mean differences in continuous variables across infection groups. All statistical analyses were conducted using R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).

Results {#S6}
=======

Overall, the 5 sera tested on the coronavirus antigen microarray all showed high IgG seroreactivity to antigens from common human coronaviruses and other respiratory viruses with known seasonal circulation versus low IgG seroreactivity to antigens from epidemic viruses that were not circulating at time of collection ([Figure 2](#F2){ref-type="fig"}). Specifically, 4 of the 5 sera showed high IgG seroreactivity across the 4 common human coronaviruses, while all of the sera showed low IgG seroreactivity to SARS-CoV-2, SARS-CoV, and MERS-CoV. All 5 sera showed high IgG seroreactivity to RSV and parainfluenza viruses, while 3 of the 5 sera showed high IgG seroreactivity to adenoviruses. For influenza, all 5 sera showed high IgG seroreactivity to H1N1 and H3N2 influenza A and influenza B strains but low IgG seroreactivity to H5N1 and H7N9 influenza A strains.

With respect to specific antigens, the S1 domain of the spike protein including the receptor-binding domain (RBD) demonstrates very low cross-reactivity between epidemic coronaviruses and common human coronaviruses, whereas the S2 domain of the spike protein and the nucleocapsid protein (NP) show low-level cross-reactivity between these coronavirus subtypes. Similarly, the head domain of influenza hemagglutinin (HA1) is not cross-reactive between seasonal and avian influenza strains, whereas the stalk domain (HA2) is cross-reactive between influenza virus subgroups, as seen between H1N1 and H5N1 influenza viruses.

Discussion {#S7}
==========

This pilot study yields several insights into cross-reactivity of common human coronavirus antibodies for SARS-CoV-2 antigens. The antibodies to the S1 and RBD domains of spike protein are highly subtype-specific, consistent with the high variability in these sequences between different human coronaviruses. Conversely, the S2 domain of spike protein and NP protein are more cross-reactive, consistent with these sequences being highly conserved across coronaviruses. SARS-CoV-2 has caused a worldwide pandemic despite likely pre-existing cross-reactive antibodies to S2 domain and NP protein in most people, indicating that these antibodies are likely not protective, whereas antibodies to S1 and RBD domains are more likely to be protective. This observation favors a vaccination strategy based on S1 or RBD domains of spike protein over a vaccination strategy that also includes S2 domain or NP protein. In addition, S1 and RBD domains are more likely to generate subtype-specific serologic tests for population surveillance studies.

In addition, a key unexplained finding during the SARS-CoV-2 epidemic has been the low incidence of infection in children aged 15 and younger. This observation generates two related hypotheses: adults may have pre-existing antibodies against antigenically distinct coronaviruses that produce an ineffective humoral response to SARS-CoV-2 infection (antibody-dependent enhancement as demonstrated for dengue virus), or children younger than 15 may have initially encountered a coronavirus that is more closely related to SARS-CoV-2 so are more protected against this infection (immunologic imprinting or original antigenic sin as demonstrated for influenza virus). Both of these hypotheses would be informed by comparing the level of cross-reactive coronavirus antibodies in pediatric and adult cohorts and correlating these antibodies with incidence of severe disease.

Conclusions {#S8}
===========

A coronavirus antigen microarray has been constructed with antigens from epidemic coronaviruses including SARS-CoV-2 and common human coronaviruses, in addition to other common respiratory viruses. A pilot study of 5 naïve human sera shows high IgG seroreactivity to common human coronaviruses but low IgG seroreactivity to SARS-CoV-2, with some cross-reactivity seen for S2 domain of spike protein and nucleocapsid protein. Further studies are needed including with SARS-CoV-2 convalescent sera to fully realize the potential of this novel methodology to characterize the seroprevalence of SARS-CoV-2 and the impact of pre-existing cross-reactive antibodies on the disease course.
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![Schematic of antigen microarray printing, probing, imaging, and analysis. Reprinted with permission^[@R6]^.](nihpp-2020.03.24.006544-f0001){#F1}
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###### 

Content of coronavirus antigen microarray.

  Virus                 Subtypes                                 Antigens   Replicates   Spots
  --------------------- ---------------------------------------- ---------- ------------ ---------
  **Coronavirus**       HKU1, OC43, NL63, 229E                   12         4            48
  MERS                  9                                        4          36           
  SARS                  5                                        4          20           
  2019-nCoV             7                                        4          28           
  **Total**                                                      **33**                  **132**
                                                                                         
  **RSV**               A, B                                     8          4            32
  **Metapneumovirus**   A, B                                     3          4            12
  **Parainfluenza**     1, 3, 4                                  5          4            20
  **Adenovirus**        3, 4, 7                                  6          4            24
  **Influenza**         H1N1, H3N2, H5N1, H7N9, B(Yam), B(Vic)   12         4            48
  **Total**                                                      **34**                  **136**

###### 

Coronavirus antigens on microarray.

  Virus             Subtype     Strain       Protein   UniProt/GenBank   Expression     Synthesis         Construct               Catalogue No
  ----------------- ----------- ------------ --------- ----------------- -------------- ----------------- ----------------------- --------------
  **Coronavirus**   NL63        NL63         S1        A0A1L2YVI8        HEK293         Sino Biological   N-(AA19-717)-His-C      40600-V08H
  **Coronavirus**   NL63        NL63         S1+S2     A0A1L2YVI8        Insect Cells   Sino Biological   N-(AA19-1296)-His-C     40604-V08B
  **Coronavirus**   229E        229E         S1        A0A1L7B942        HEK293         Sino Biological   N-(AA16-536)-His-C      40601-v08H
  **Coronavirus**   229E        229E         S1+S2     A0A1L7B942        Insect Cells   Sino Biological   N-(AA16-1115)-His-C     40605-V08B
  **Coronavirus**   HKU1        HKU1         S1        YP_173238.1       HEK293         Sino Biological   N-(AA1-760)-His-C       40021-V08H
  **Coronavirus**   HKU1        HKU1         S1        Q0ZME7            HEK293         Sino Biological   N-(AA13-756)-His-C      40602-V08H
  **Coronavirus**   HKU1        HKU1         S1+S2     Q0ZME7            Insect Cells   Sino Biological   N-(AA13-1295)-His-C     40606-V08B
  **Coronavirus**   HKU1        HKU1         HE        Q0ZME7            HEK293         Sino Biological   N-(AA16-394)-His-C      Custom
  **Coronavirus**   HKU23       HKU23-368F   NP        AHN64796.1        HEK293         Sino Biological   N-(AA1-448)-His-C       40458-V08B
  **Coronavirus**   OC43        OC43         S1        AVR40344.1        HEK293         Sino Biological   N-(AA13-533)-His-C      Custom
  **Coronavirus**   OC43        OC43         S1+S2     AVR40344.1        Insect Cells   Sino Biological   N-(AA13-1304)-His-C     40607-V08B
  **Coronavirus**   OC43        OC43         HE        ATN39879.2        HEK293         Sino Biological   N-(AA16-394)-His-C      40603-V08H
  **Coronavirus**   MERS        MERS         S1-RBD    AFS88936.1        Insect Cells   Sino Biological   N-(AA383-502)-Fc-C      40071-V05B
  **Coronavirus**   MERS        MERS         S1-RBD    AFS88936.1        Insect Cells   Sino Biological   N-(AA383-502)-rFc-C     40071-V31B
  **Coronavirus**   MERS        MERS         S1-RBD    AFS88936.1        Insect Cells   Sino Biological   N-(AA367-606)-rFc-C     40071-V31B1
  **Coronavirus**   MERS        MERS         S1-RBD    AFS88936.1        Insect Cells   Sino Biological   N-(AA367-606)-His-C     40071-V08B1
  **Coronavirus**   MERS        MERS         S1        AFS88936.1        HEK293         Sino Biological   N-(AA1-725)-His-C       40069-V08H
  **Coronavirus**   MERS        MERS         S1        AFS88936.1        Insect Cells   Sino Biological   N-(AA1-725)-His-C       40069-V08B1
  **Coronavirus**   MERS        MERS         S1+S2     AFS88936.1        Insect Cells   Sino Biological   N-(AA1-1297)-His-C      40069-V08B
  **Coronavirus**   MERS        MERS         S2        AFS88936.1        Insect Cells   Sino Biological   N-(AA726-1296)-His-C    40070-V08B
  **Coronavirus**   MERS        MERS         NP        AFS88943.1        Insect Cells   Sino Biological   N-(AA1-413)-His-C       40068-V08B
  **Coronavirus**   SARS        SARS         S1-RBD    AAX16192.1        Insect Cells   Sino Biological   N-(AA306-527)-Fc-C      40150-V31B2
  **Coronavirus**   SARS        SARS         S1-RBD    AAX16192.1        Insect Cells   Sino Biological   N-(AA306-527)-His-C     40150-V08B2
  **Coronavirus**   SARS        SARS         S1        AAX16192.1        Insect Cells   Sino Biological   N-(AA1-667)-His-C       40150-V08B1
  **Coronavirus**   SARS        SARS         NP        NP_828858.1       Insect Cells   Sino Biological   N-(AA1-422)-His-C       40143-V08B
  **Coronavirus**   SARS        SARS         PLpro     AAX16193.1        E. coli        Sino Biological   N-(AA1541-1859)-His-C   40524-V08E
  **Coronavirus**   2019-nCoV   2019-nCoV    S1-RBD                      HEK293         Sino Biological   N-(AA)-mFc-C            40592-V05H
  **Coronavirus**   2019-nCoV   2019-nCoV    S1                          HEK293         Sino Biological   N-(AA)-His-C            40591-V08H
  **Coronavirus**   2019-nCoV   2019-nCoV    S1                          HEK293         Sino Biological   N-(AA)-Fc-C             40591-V02H
  **Coronavirus**   2019-nCoV   2019-nCoV    S1                          HEK293         Sino Biological   N-(AA)-Fc-C             40591-V05H1
  **Coronavirus**   2019-nCoV   2019-nCoV    S2                          Insect Cells   Sino Biological   N-(AA)-His-C            40590-V08B
  **Coronavirus**   2019-nCoV   2019-nCoV    S1+S2                       Insect Cells   Sino Biological   N-(AA)-His-C            40589-V08B1
  **Coronavirus**   2019-nCoV   2019-nCoV    NP                          Insect Cells   Sino Biological   N-(AA)-His-C            40588-V08B

###### 

Non-coronavirus respiratory virus antigens on microarray.

  Virus               Subtype   Strain                 Protein   UniProt/GenBank   Expression     Synthesis         Construct             Catalogue No
  ------------------- --------- ---------------------- --------- ----------------- -------------- ----------------- --------------------- --------------
  **RSV**             A         LA2-94/2013            F         A0A023RA53        Insect Cells   Sino Biological   N-(AA1-526)-His-C     Custom
  **RSV**             A         LA2-94/2013            G         A0A076FRQ0        HEK293         Sino Biological   N-(AA64-321)-His-C    Custom
  **RSV**             A         A2                     F                           Insect Cells   Sino Biological   N-(AA1-529)-His-C     11049-V08B
  **RSV**             A         rsb1734                G                           HEK293         Sino Biological   N-(AA66-297)-His-C    11070-V08H
  **RSV**             A         RSS-2                  F                           Insect Cells   Sino Biological   N-(AA1-529)-His-C     40037-V08B
  **RSV**             B         TH-10526/2014          F         K7WLI9            Insect Cells   Sino Biological   N-(AA1-525)-His-C     Custom
  **RSV**             B         TH-10526/2014          G         A0A142MLK4        HEK293         Sino Biological   N-(AA64-310)-His-C    Custom
  **RSV**             B         B1                     G                           HEK293         Sino Biological   N-(AA67-299)-His-C    13029-V08H
  **hMPV**            A         PER/CFI0320/2010/A     G                           HEK293         Sino Biological   52N-228N-His          Custom
  **hMPV**            B         PER/CFI0466/2010/B     G                           HEK293         Sino Biological   52D-238S-His          Custom
  **hMPV**            B         PER/CFI0320/2010/A     F                           HEK293         Sino Biological   280D-490G-His         Custom
  **Parainfluenza**   1         12O3                   F         A0A1V0E1X5        Insect Cells   Sino Biological   N-(AA22-497)-His-C    Custom
  **Parainfluenza**   1         12O3                   H         A0A1B2CW87        Insect Cells   Sino Biological   N-His-(AA60-575)-C    Custom
  **Parainfluenza**   3         USA/10991B/2010        H         T1UD13            Insect Cells   Sino Biological   N-His-(AA55-575)-C    Custom
  **Parainfluenza**   4         hPIV-4b/10-H2/2016     F         A0A1V0E1N6        Insect Cells   Sino Biological   N-(AA22-486)-His-C    Custom
  **Parainfluenza**   4         hPIV-4b/10-H2/2016     H         A0A1V0E1N4        Insect Cells   Sino Biological   N-His-(AA48-575)-C    Custom
  **Adenovirus**      3         hAdV-3/45659           Fiber     P04501            E. coli        Sino Biological   N-His-\[Prot\]-C      Custom
  **Adenovirus**      3         hAdV-3/45659           Penton    Q2Y0H9            Insect Cells   Sino Biological   N-His-\[Prot\]-C      Custom
  **Adenovirus**      4         hAdV-4/28280           Fiber     P36844            Insect Cells   Sino Biological   N-\[Prot\]-His-C      Custom
  **Adenovirus**      4         hAdV-4/28280           Penton    Q2KSF3            Insect Cells   Sino Biological   N-\[Prot\]-His-C      Custom
  **Adenovirus**      7         Adeno7 10519           Fiber     P15141            Insect Cells   Sino Biological   N-His-\[Prot\]-C      Custom
  **Adenovirus**      7         Adeno7 10519           Penton    Q2KS58            Insect Cells   Sino Biological   N-\[Prot\]-His-C      Custom
  **Influenza**       H1N1      A/Beijing/22808/2009   HA1       ADD64203.1        HEK293         Sino Biological   N-(AA1-344)-His-C     40035-V08H1
  **Influenza**       H1N1      A/Beijing/22808/2009   HA1+HA2   ADD64203.1        HEK293         Sino Biological   N-(AA1-529)-His-C     40035-V08H
  **Influenza**       H3N2      A/Texas/50/2012        HA1       AGL07159.1        HEK293         Sino Biological   N-(AA1-345)-His-C     40354-V08H1
  **Influenza**       H3N2      A/Texas/50/2012        HA1+HA2   AGL07159.1        Insect Cells   Sino Biological   N-(AA1-530)-His-C     40354-V08B
  **Influenza**       B         B/Malaysia/2506/2004   HA1       CO05957.1         HEK293         Sino Biological   N-(AA1-362)-His-C     11716-V08H1
  **Influenza**       B         B/Malaysia/2506/2004   HA1+HA2   CO05957.1         HEK293         Sino Biological   N-(AA1-556)-His-C     11716-V08H
  **Influenza**       B         B/Phuket/3073/2013     HA1       EPI529345         HEK293         Sino Biological   N-(AA1-361)-His-C     40498-V08H1
  **Influenza**       B         B/Phuket/3073/2013     HA1+HA2   EPI529345         Insect Cells   Sino Biological   N-(AA1-547)-His-C     40498-V08B
  **Influenza**       H5N1      A/Vietnam/1203/2004    HA1       AAW80717.1        HEK293         Sino Biological   (AA1-342)-mFcg1-His   10003-V06H1
  **Influenza**       H5N1      A/Vietnam/1203/2004    HA1+HA2   AAW80717.1        HEK293         Sino Biological   (AA1-531)-mFcg1-His   10003-V06H3
  **Influenza**       H7N9      A/Anhui/1/2013         HA1       AGJ51953.1        HEK293         Sino Biological   N-(AA1-338)-His-C     40103-V08H1
  **Influenza**       H7N9      A/Anhui/1/2013         HA1+HA2   AGJ51953.1        HEK293         Sino Biological   N-(AA1-524)-His-C     40103-V08H
